Investigational drug · Phase 3
Sapablursen
Also called: ISIS 702843, ONO-0530, IONIS-TMPRSS6-LRx
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Polycythemia Vera, Phlebotomy Dependent Polycythemia Vera.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "Sapablursen"
First trial start
2021
Dec 30, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sapablursen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Polycythemia Vera
- Phlebotomy Dependent Polycythemia Vera
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Sapablursen" as an intervention, largest first.
- INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)Pivotal-lookingRecruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT07429266 · 250 participants (planned) · Start May 25, 2026 · Primary completion Sep 2028
Drug: Sapablursen; Placebo · For: Polycythemia Vera
Sites: Orange, California; Miami, Florida; Plantation, Florida · 38 sites in all
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05143957 · 50 participants · Start Dec 30, 2021 · Primary completion Jun 26, 2025
Drug: sapablursen · For: Phlebotomy Dependent Polycythemia Vera
Sites: Birmingham, Alabama; Phoenix, Arizona; Hackensack, New Jersey · 13 sites in all
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT04059406 · 29 participants · Start Sep 24, 2020 · Primary completion Mar 28, 2023
Drug: sapablursen · For: Beta Thalassemia Intermedia
Sites: Camperdown, Australia; Clayton, Australia; Perth, Australia · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A phase 2a randomized study to evaluate sapablursen in patients with non-transfusion-dependent β-thalassemia intermedia.
Taher A, Diamantidis MD, Kattamis A, et al. · Blood Adv 2026
- Sapablursen for erythrocytosis control in patients with polycythemia vera.
Palmer JM, How J, Bose P, et al. · Blood 2026
- Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis.
Kremyanskaya M, Ginzburg YZ, Hoffman R · Blood 2026
- Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry N-Acetyl-galactosamine Conjugate that Targets the Human Transmembrane Protease Serine 6.
Zanardi TA, Korbmacher B, Boone L, et al. · J Pharmacol Exp Ther 2021
Also in development for Polycythemia Vera
- BomedemstatMK-3543, IMG-7289Phase 35 trials
Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- AG-236Phase 31 trial
Agios Pharmaceuticals, Inc. · Polycythemia Vera
- JBI-802Phase 21 trial
Jubilant Therapeutics Inc. · Essential Thrombocythemia (ET), Polycythemia Vera
- SLN124Phase 21 trial
Silence Therapeutics plc · Polycythemia Vera
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.